When was Morphoceuticals founded?

Morphoceuticals was founded in 2020 and raised its 1st funding round 3 years after it was founded.

Where is Morphoceuticals located?

Morphoceuticals is headquartered in Marblehead, United States.

How many employees does Morphoceuticals have?

As of Aug 31, 2026, the latest employee count at Morphoceuticals is 6.

Is Morphoceuticals a funded company?

Morphoceuticals is a funded company, having raised a total of $13.3M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 23, 2023.

When was the latest funding round of Morphoceuticals?

Morphoceuticals' latest funding was a $***** Seed round on Sep 23, 2024, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.75B in funding in 2026 to date.

Where does Morphoceuticals rank among its competitors?

Morphoceuticals ranks 1145th amongst 2925 active competitors, of which 979 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Morphoceuticals?

Morphoceuticals' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Morphoceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of reprogramming software to regenerate tissues and organs. The company is pioneering the bioelectric reprogramming of biology to treat complex health states by targeting native bioelectric signaling to reprogram biology that can regenerate tissues and organs, including the brain. It has applications for Amputation stump health, Limb regeneration, and Organogenesis.

Website: www.morphoceuticals.com/
Email ID: *****@morphoceuticals.com

Key Metrics

Founded Year

2020

Location

Marblehead, United States

Stage

Seed

Total Funding

$13.3M in 2 rounds

Latest Funding Round

Seed, Sep 23, 2024, $*****

Investors

Prime Movers Lab & 1 more

Ranked

1145^th among 2925 active competitors

Employee Count

6 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 603 more

View Morphoceuticals' full profile

Morphoceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Morphoceuticals, Inc. CIN: 844555716 , United States, Active	Dec 31, 2019	-	-	-

Morphoceuticals has raised a total funding of $13.3M over 2 rounds. Its first funding round was on Jan 23, 2023. Morphoceuticals has 2 institutional investors.

Here is the list of recent funding rounds of Morphoceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 23, 2024	3211211	Seed	8481534	4028196	2687162	4345663
Jan 23, 2023	6216724	Seed	1095137	9519492	Prime Movers Lab	Juvenescence

Access funding benchmarks and valuations. Sign up today!

View details of Morphoceuticals's funding rounds and investors

The founders of Morphoceuticals are David Kaplan and Michael Levin.

Here are the details of Morphoceuticals' key team members:

David Kaplan: Co-Founder of Morphoceuticals.
Contact Info: 1 email address
Michael Levin: Co-Founder of Morphoceuticals.
Contact Info: 1 email address

View details of Morphoceuticals's Founder profiles and Board Members

Morphoceuticals' employee count trend

Morphoceuticals has 6 employees as of Aug 26. Here is Morphoceuticals's employee count trend over the years:

Employee count trend for Morphoceuticals

Uncover Morphoceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Morphoceuticals include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Morphoceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
1145th	Morphoceuticals 2020, Marblehead (United States), Seed	Developer of reprogramming software to regenerate tissues and organs	$13.3M	Prime Movers Lab, Juvenescence	37/100